

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**VOLUNTARY ANNOUNCEMENT
FIRST COMMERCIAL SHIPMENT OF
INSULIN GLARGINE INJECTION TO THE UNITED STATES**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of Directors of the Company (the “**Directors**”) is pleased to announce that the Group’s self-developed Insulin Glargine Injection (Langlara) has commenced commercial shipment to the United States market. The first batch of shipments is planned to comprise a total of 1,152,000 prefilled pens, which will be delivered in batches in an orderly manner and the delivery is expected to be completed by mid-to-late August 2026. The commercial shipment of the insulin product to the United States marks a major milestone breakthrough in the Group’s international expansion and overseas commercialization strategy.

The Group’s self-developed Insulin Glargine Injection has received an approval letter from the United States Food and Drug Administration (“**FDA**”) at the end of April 2026, making it the fourth insulin glargine product approved for marketing in the United States, and the Company the first PRC pharmaceutical company to commercialize an insulin glargine product in the United States market. It is a significant milestone in the Company’s internationalisation strategy. In addition, the product has been designated by the FDA as an “interchangeable biosimilar”, the highest regulatory designation available under the FDA’s biosimilar pathway. With this designation, the product is permitted to be substituted for the reference product at the pharmacy level in the United States without requiring a new prescription from the prescribing physician, which can effectively lower market access barriers for products, accelerate product distribution across terminal channels, and drive rapid market volume expansion, providing a significant competitive advantage in the market.

The Group’s insulin glargine is a third-generation insulin analogue that allows for once-daily administration. It was the world’s first once-daily long-acting insulin analogue, originally developed by Sanofi of France and marketed under the brand name Lantus®. According to QYResearch, the global insulin glargine market is expected to reach nearly US\$10 billion in

size, with the United States representing the world's largest insulin glargine market and accounting for more than 60% of the global market that is backed by ample market demand and broad room for growth.

Drawing on its longstanding presence in the field of diabetes medications, the Group boasts a comprehensive portfolio of insulin biosimilar products to meet the clinical needs of physicians and patients. On 30 July 2026, the Group's self-developed Insulin Degludec Injection was officially approved for marketing by the National Medical Products Administration (NMPA) of the PRC, available in two specifications: cartridges and pre-filled pens. With the approval of this product for market launch, the number of the Group's approved insulin products in the Chinese market has increased to six, establishing a full-range insulin product matrix that spans the second to fourth generations and covers three major clinical application scenarios: basal, prandial, and pre-mixed insulins.

In terms of the R&D pipeline, the Group's Insulin Degludec and Insulin Aspart Injection is currently under marketing registration review, while HEC-151, an innovative ultra-long-acting weekly insulin formulation, has entered Phase I clinical trials. Moving forward, these candidates will form a multi-tiered product echelon comprising "daily formulations — weekly formulations — combination formulations" alongside currently marketed products, enabling the continuous iterative upgrading of the Group's insulin product pipeline.

The Group has established a production base in Yidu City, Hubei Province that covers the entire value chain of insulin products and their analogs. Currently, the Group has obtained four regulatory approvals for insulin active pharmaceutical ingredients and eleven approvals for insulin drug products (including various presentations such as prefilled pens). The designed annual production capacity of insulin drug products exceeds 100 million units, providing the Group with large-scale and sustainable manufacturing capabilities to ensure stable supply to overseas markets. Previously, the Company received an order from a United States partner for no less than 18 million units, and this shipment represents the first batch of commercial deliveries under such cooperation framework.

In terms of its international product portfolio, the Group is simultaneously advancing the overseas registration and commercialization of several insulin products. Among them, glargine insulin injection has been approved for marketing in the United Arab Emirates, Bahrain, Algeria, Mali, and Niger; aspart insulin injection has been approved for marketing in the United Arab Emirates, Bahrain, Algeria, and Niger, with R&D efforts for the U.S. market proceeding in an orderly manner; and aspart insulin 30 injection has been approved for marketing in United Arab Emirates, Bahrain; while insulin degludec is scheduled for biosimilar clinical trial applications in the United States and Europe, as we continues to strengthen our product pipeline for overseas markets.

At present, the Group's insulin products have been successfully commercialized in a number of overseas markets, including the Middle East, South-East Asia. This year, we also plan to further expand our commercial footprint in regions such as North Africa, West Africa, and South America. The successful entry of our insulin glargine injection into the U.S. market represents a significant milestone for domestically developed insulin biosimilars in expanding into major global pharmaceutical markets, marking the evolution of the Company's internationalization strategy from exporting products and technologies to achieving large-scale commercialization.

Going forward, the Group will continue to advance the global expansion of its insulin product portfolio, expand its international market share, enhance its international operational capabilities and brand influence, and bring PRC-developed insulin products to the global market to benefit people with diabetes worldwide.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
31 July 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.